


# Analyzing Fusion Genes with Next-Generation Sequencing Technology



Raed Samara, Ph.D Global Product Manager







- QIAGEN products shown here are intended for molecular biology applications. These products are not intended for the diagnosis, prevention or treatment of a disease.
- For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.




- 1 Fusion genes: What they are and their historical perspective
- 2 Fusion gene detection: Current status
- 3 RNA sequencing vs. digital RNA sequencing
- 4 How to detect and accurately quantify novel fusion genes in your sample



# 1 Fusion genes: What they are and their historical perspective


- 2 Fusion gene detection: Current status
- 3 RNA sequencing vs. digital RNA sequencing
- 4 How to detect and accurately quantify novel fusion genes in your sample







A new gene formed by the chromosomal translocation of two parts of different genes





Source: Leonard, G. [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons https://upload.wikimedia.org/wikipedia/commons/b/b0/Gene\_Fusion\_Types.png



They are implicated in hematologic and soft tissue malignancies...

#### Timeline of gene fusion discoveries in: Hematologic malignancies






Source: Kumar-Sinha, C., Kalyana-Sundaram, S., Chinnaiyan, A.M. (2015) Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 7, 129.



And in rare and common epithelial cancer...




Source: Kumar-Sinha, C., Kalyana-Sundaram, S., Chinnaiyan, A.M. (2015) Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 7, 129.




- 1 Fusion genes: What they are and their historical perspective
- 2 Fusion gene detection: Current status
- 3 RNA sequencing vs. digital RNA sequencing
- 4 How to detect and accurately quantify novel fusion genes in your sample







At an unprecedented rapid pace...



Source: Mertens, F., Johansson, B., Fioretos, T., Mitelman, F. (2015) The emerging complexity of gene fusions in cancer. Nat Rev Cancer 15, 371-81.



## Current technologies: Advantages and disadvantages


Current technology	Advantages	Disadvantages
PCR-based	Accuracy	Limited sample and assay throughput Requires a lot of RNA
Whole transcriptome sequencing (WTS)	Throughput power	Expensive Complex data
FISH (Fluorescence in situ hybridization)	Established method for routine testing	Laborious
Conventional Targeted RNA sequencing	Manageable data Relatively low per-sample cost	PCR duplicates, which limit the sensitivity of the panel and reduce the ability to confidently detect low-abundance fusions



- 1 Fusion genes: What they are and their historical perspective
- 2 Fusion gene detection: Current status
- 3 RNA sequencing vs. digital RNA sequencing
- 4 How to detect and accurately quantify novel fusion genes in your sample




PCR amplification is required for target enrichment, but...






#### PCR duplicates limit accurate quantification





Capture and freeze original status of fusion transcripts by tagging them before any amplification





Tag (barcode) to identify unique RNA molecules


# TATCGTACAGAT

(12 nucleotides long)

Incorporate this random barcode (signature) into the original RNA molecules (before amplification) to preserve their uniqueness



#### Count and analyze single original molecules (not total reads) = digital sequencing






- 1 Fusion genes: What they are and their historical perspective
- 2 Fusion gene detection: Current status
- 3 RNA sequencing vs. digital RNA sequencing
- 4 How to detect and accurately quantify novel fusion genes in your sample




#### QIAseq targeted RNAscan workflow





Panels, molecularly-barcoded (UMI) adapters and data analysis algorithms






# QIAGEN's solution: QIAseq targeted RNAscan Panels

Current technology	Disadvantages	How QIAseq targeted RNAscan panels address disadvantages of current technologies
PCR-based	Limited sample and assay throughput Requires a lot of RNA	Profile hundreds of gene fusions in up to 384 samples simultaneously Requires 10 ng RNA
Whole transcriptome sequencing (WTS)	Expensive Complex data	Cost-effective Easy data analysis
FISH (Fluorescence in situ hybridization)	Laborious	Streamlined, automation-friendly protocol
Conventional Targeted RNA sequencing	PCR duplicates, which reduce the ability to confidently detect low-abundance fusions	Digital sequencing removes PCR duplicates to increase sensitivity of panel, and detect low-abundance fusions



As low as 10 ng

QIAseq Targeted RNAscan Panel: Workflow






#### RNA conversion step is crucial

More RNA converted — More fusions detected

- Test kits:
  - QIAseq Targeted RNAscan panel kit
  - o Competitor A panel kit
- Sample: For each reaction,10 ng universal RNA spiked with 1 pg of an artificial RNA molecule.
- Follow each kit's standard workflow to generate 2<sup>nd</sup> strand product.
- Detect converted spike-in RNA with qPCR
- Result showed RNAscan has superior RNA conversion efficiency.
- Higher conversion efficiency means higher sensitivity, especially with low input.




	RNAscan	Α		
$C_{T}$ (average+/-SD)	22.8 +/- 0.05	38.5 +/- 0.53		




As low as 10 ng

QIAseq Targeted RNAscan Panel: Workflow







QIAseq Targeted RNAscan Panel: Workflow






#### Count and analyze single original molecules (not total reads) = digital sequencing










#### SPE



No need for long fragments to give space for two primers apart from the fusion junction, so shorter fragments are better tolerated. This approach will help deal with FFPE sample challenges where many RNA fragments may not have enough length to cover both GS1 and GS2 sequence in competitor A panels. Competitor A panels might require longer fragments, which will reduce the efficiency of PCR and the crossing of spanning reads across fusion junctions.



Nested PCR

One gene/target-specific	Two gene/target-specific
primer	primers

- Flexibility in primer design
- Generate relatively small library fragments to maintain compatibility with fragmented RNA (FFPE samples)



## Design based on junction


Primers target both ends of a fusion




fusion pair	5' chr	start	end	strand	3' chr	start	end	strand	ENSTs and exons
ETV6-	ETV6- NTRK3 12 11	11853560 11853561	11052561		15 87	87940752	87940753	-	ETV6 (ENST00000396373) exon 4 to
NTRK3		11823200	11853561	+					NTRK3 (ENST00000394480) exon 15




Exon- or gene-based design for unknown partners








QIAseq Targeted RNAscan Panel: Workflow (I)






QIAseq Targeted RNAscan Panel: Workflow (I)





QIAseq Targeted RNAscan Panel: Workflow (L)





Feature	Benefit
Low RNA input (as low as 10 ng of unenriched RNA)	Preserve sample
Unique RNA conversion chemistry	Convert more RNA to cDNA to detect more fusions
Unique molecular indices (UMIs)	Enables single molecule counting, removal of PCR duplicates and error correction; these features correct for amplification bias, distinguish clonal replicates and deliver absolute measurements of fusion transcripts
High primer multiplexing capability (up to 1000 primers)	Detects a large number of fusions
Single pool of primers	Easier sample handling
SPE-based target enrichment	Flexibility in primer design Generate relatively small library fragments to maintain compatibility with fragmented RNA (FFPE samples)
High sample multiplexing (up to 384 samples)	Increased sample throughput to decrease sequencing costs
No prior knowledge of breakpoint needed	Discover novel partners
Automation-friendly workflow	Streamline operations for high throughput
Suite of complementary data analysis tools	Save resources
Very cost-effective compared to competition	Save \$\$\$



Two boxes are needed to support the workflow

## Panel box (kit)



- Reagents for cDNA synthesis
- Fusion-specific primers for enrichment
- All required buffers and enzymes
- Magnetic beads

#### Index box (kit)



 Molecularly-barcoded library adapters, primers to prepare libraries that are sample indexed and sequencing platform-specific

#### At a glance

#### Panels

- RNAscan
  - Cataloged
  - Custom
  - Extended

## Indices

- Illumina
  - 12-index
  - 96-index (4 sets, for up to 384-plex)
- Ion Torrent
  - o 12-index
  - o 96-index



#### List of panels

Panel	Variant (cat) number	Number of primers	Types of coverage
Hematology panel	FHS-001Z	156	Breakpoint
Solid tumor panel	FHS-002Z	101	Breakpoint
Lung cancer panel	FHS-003Z	137	Breakpoint
Oncology panel	FHS-3001Z	950	Breakpoint

Primers target both ends of a fusion

←

#### For QIAseq targeted RNAscan panels

Cat ID	Name	Sequencing platform	Number of samples per sequencing run that can be multiplexed	Number of samples each kit (SAP ID) can process
333714	QIAseq 12-Index I (48)	Illumina	12 samples per sequencing run	48 samples
333727	QIAseq 96-Index I Set A (384)	Illumina	96 samples per sequencing run	384 samples
333737	QIAseq 96-Index I Set B (384)	Illumina	96 samples per sequencing run (192 if used with Set A)	384 samples
333747	QIAseq 96-Index I Set C (384)	Illumina	96 samples per sequencing run (288 if used with Sets A, B)	384 samples
333757	QIAseq 96-Index I Set D (384)	Illumina	96 samples per sequencing run (384 if used with Sets A, B, C)	384 samples
333764	QIAseq 12-Index L (48)	Ion Torrent	12 samples per sequencing run	48 samples
333777	QIAseq 96-Index L (384)	Ion Torrent	96 samples per sequencing run	384 samples

00000

QIAGEN



Application: Proof of sensitivity and specificity of the QIAseq Targeted RNAscan panels

- Engineered positive control for 12 popular fusions as testing material
- QIAseq Targeted RNAscan panel was designed based on fusion's breakpoint and sequence used from both genes
- Control FFPE sample was used with 15 ng as starting material; same amount of normal universal RNA was used as negative control
- Library was run with sequencer MiSeq
- Fusion was detected with current QIAseq Targeted RNAscan data analysis pipeline

# Fusion Partners included

	RNA Fusion	Primary Cancer Tissue
1	EML4-ALK	Lung
2	NPM1-ALK	Lymphoid
3	KIF5B-RET	Lung
4	NCOA4-RET	Thyroid
5	CD74-ROS1	Lung
6	SLC34A2-ROS1	Lung, Stomach
7	TPM3-NTRK1	Lung, Large Intestine
8	TFG-NTRK1	Thyroid (rare)
9	FGFR3-BAIAP2L1	Urinary tract (rare)
10	FGFR3-TACC3	Urinary tract, CNS
11	PAX8-PPARG	Thyroid
12	ETV6-NTRK3	Kidney, Breast, Soft Tissue



#### 100% sensitivity (12/12 positive), 0% positive

Fusion in sample	UMIs for detected crossing-junction reads
EML4-ALK	18
NPM1-ALK	5
KIF5B-RET	25
NCOA4-RET	46
CD74-ROS1	11
SLC34A2-ROS1	8
TPM3-NTRK1	46
TFG-NTRK1	5
FGFR3-BAIAP2L1	37
FGFR3-TACC3	60
PAX8-PPARG	28
ETV6-NTRK3	30

#### All fusions in control were detected with at least 5 MTs

Sample to Insight

Analyzing Fusion Genes with Next-Generation Sequencing Technology, 11.20.2016



Example of positive fusion detected: In positive controls, FGFR3-TACC3 fusion is one the 12 positive fusions

#### FGFR3--TACC3

#### Summary

Role	Gene(s)	Donor		Acceptor		Links	Crossing		Spanning			
		Chr	Position	Strand	Chr	Position	Strand	LIIIKS	Reads	Tags	Reads	Tags
Donor	FGFR3	chr4	1,806,935	+	chr4	1,807,115	+	1	32	15	0	0
Acceptor	TACC3	chr4	1,739,701	+	chr4	1,739,701	+	2	720	459	0	0
Fusion	FGFR3TACC3	chr4	1,806,935	+	chr4	1,739,701	+	1	99	60	0	0



Confidently detect lowabundance fusions

Molecular barcodes

- Correct for PCR duplicates
- Unmatched sensitivity

Flexibility to detect known and novel fusions

#### Single primer extension and powerful pipelines

- Only one of the two targets need to be known/targeted
- Targets are defined based on breakpoint, exons or genes



#### Completely integrated and optimized workflow: From Sample to Insight

#### Digital sequencing with molecular barcodes

• Remove PCR duplicates and errors for accurate quantification

#### Barcode-aware, comprehensive data analysis pipelines

Confidently call low-abundance fusion transcripts and identify novel variants

#### Single primer extension approach

• No need for nested PCR primer design; ability to detect more fusions

#### Throughput flexibility

• Molecularly profile hundreds of fusion transcripts in hundreds of samples, simultaneously

#### Compatibility with fragmented or preserved RNA

• Sequence RNA from FFPE samples or liquid biopsy samples

#### Fast custom design and manufacturing turnaround time

• Receive custom panel or extend an existing panel in 2–3 weeks.



- Barcode-aware fusion caller has been developed
- Caller is available on the cloud
- In conjunction with molecular barcodes incorporated in the workflow, the caller can confidently call low-abundance fusions (down to 1% expression level)
- Fusion caller will do the following:
  - Mapping
  - o Alignment
  - Molecular barcode counting
  - Fusion calling
  - Fusion annotation based on internal curated database



Inputs

FASTQ or BAM files are uploaded into cloud-based data analysis portal

The following inputs are needed (by user):

- Set up file
- Panel used
- File lanes
  - 1-lane (MiSeq/HiSeq/NextSeq concatenated)
  - 4-lane (NextSeq individual lane files)




#### Outputs

## Summary file


- Stats
  - Specificity
  - Uniformity
  - Molecular barcode counts
- Fusions
  - o Curated/novel/no reference available
  - Statistical confidence
  - Graphical representations








#### Different panels can be plugged into the same targeted NGS workflow











# **Questions?**



## Contact QIAGEN Call: 1-800-426-8157 Email: techservice-na@QAGEN.com BRCsupport@QIAGEN.com QIAseq.NGS@QIAGEN.com

QIAWebinars@QIAGEN.com